10月8日，Revolution Medicines盘中下跌5.28%，报190.2美元/股，成交额6493.89万美元。此前一日RBC将目标价从251美元上调至259美元并维持跑赢大盘评级，但未能阻止股价回落，市场或对前期累计涨幅进行获利了结。
公司所在的生物科技行业中，整体表现疲软，个股中，Argenx SE下跌12.08%，Twist Bioscience下跌4.28%，Natera下跌2.04%，艾伯维下跌0.34%，Moderna下跌0.29%。行业普跌对RVMD形成拖累。
Revolution Medicines是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法以抑制RAS成瘾癌症的前沿靶点，拥有先进的基于结构的药物发现能力及针对RAS通路关键信号节点的深层研发管线。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.